Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies built on its TransCon technology platform. The company is headquartered in Hellerup, Denmark and operates with additional facilities in Europe and the United States.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueApproved medicines sold in key markets, including SKYTROFA, YORVIPATH and YUVIWEL.
TransCon-based programs in development for endocrine and other therapeutic areas.
Use of the TransCon platform in partnered or collaborative programs.
Customers
Ascendis sells prescription medicines used by specialists who treat rare endocrine and related disorders. Its end customers are patients, but purchasing and access are driven by hospitals, specialty physicians, payers and pharmacy distribution channels. The business depends on adoption by clinicians and reimbursement decisions that support access to specialty therapies.
Endocrinologists and other specialists prescribe the company's therapies for rare endocrine diseases.
Patients use the company's medicines for chronic endocrine conditions requiring ongoing treatment.
Insurers and national health systems determine coverage, access and formulary positioning.
These channels distribute and administer specialty medicines to end patients.
Strategy
Ascendis’ strategy is centered on applying the TransCon platform to create differentiated therapies with best-in-class potential in unmet medical needs. The company pairs internal R&D with commercial execution for approved products, while extending the platform across additional endocrine and specialty disease opportunities.
The platform is the core source of long-term product generation and differentiation.
Approved products need physician adoption, access and repeat prescribing to scale.
A transatlantic footprint supports development, regulatory and commercial execution.
Geography
Ascendis is headquartered in Denmark and describes itself as a global biopharmaceutical company with additional facilities in Europe and the United States. The available filing excerpt does not provide a country revenue split, but the company’s operational footprint indicates a transatlantic structure that supports development, commercialization and regulatory activity in multiple markets.
Risks
The business faces the usual biopharma risks around clinical development, regulatory approval, commercialization and reimbursement, all of which can delay or limit value creation. Because Ascendis depends on a small set of specialty therapies and a platform approach, adoption, safety, competition and access dynamics can have an outsized impact on performance.
- Market access and reimbursement pressureImpact: HighLikelihood: High
Specialty drugs often depend on payer coverage and formulary placement.
Exposure - Product concentrationImpact: HighLikelihood: High
A limited commercial portfolio creates sensitivity to one product's performance.
Exposure: Revenue and operating leverage
- Clinical development failureImpact: HighLikelihood: Medium
The platform depends on successful trials to create new approved therapies.
Exposure: Pipeline programs and future product launches
- Regulatory approval riskImpact: HighLikelihood: Medium
Biopharmaceutical products require approvals and post-approval compliance.
Exposure: New drug launches and label expansion
- Competition in rare disease therapeuticsImpact: MediumLikelihood: Medium
Competing drugs and future entrants can affect physician choice and pricing.
Exposure: Endocrinology and specialty treatment markets
Accounting
Judgemental itemsManagement revises deductions based on prior-period experience and assumptions.
Impact: Affects reported net revenue and quarter-to-quarter comparability
Fair-value remeasurement depends on share price and market inputs.
Impact: Can create non-operating gains or losses in profit
Recognition reflects reassessment of recoverability of tax attributes.
Impact: Can cause one-time tax benefits and distort period comparison
The company notes that future reporting presentation may change.
Impact: May alter profit subtotal presentation without changing economics
Similar listed companies
Publicly listed companies with a comparable business focus.
Ascentage Pharma Group International - American Depository Shares
AAPG · Pharmaceutical Preparations
Ascentage Pharma Group International is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for cancer.
Ascelia Pharma
ACE · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
Ionis Pharmaceuticals, Inc
IONS · Pharmaceutical Preparations
Ionis Pharmaceuticals is a U.S.-based biotechnology company focused on RNA-targeted medicines, using antisense chemistry to discover and develop therapies for serious diseases.
BridgeBio Pharma, Inc.
BBIO · Pharmaceutical Preparations
Corcept Therapeutics Incorporated
CORT · Pharmaceutical Preparations
Corcept Therapeutics is a U.S.-based commercial-stage pharmaceutical company focused on medicines that modulate cortisol, with its core marketed product Korlym…
Last updated: 28/09/2026